Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed ...

Moderna Inc. MRNA shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on ...

Moderna and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Allergic reactions after COVID shots appear only in participants with severe allergy and/or mast cell disorder histories, but ...

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

This stock has soared more than 600% this year.

On August 5, 2026, the Food and Drug Administration approved Moderna's mFLUSIVA, the first mRNA seasonal influenza vaccine, for adults aged 50 and older. In a phase 3 clinical trial, the vaccine was ...

Still, it's a bullish development if only because it puts the company on more investors' radars. It also prompts fund ...